Literature DB >> 22367621

Which prediction models best identify additional axillary disease after a positive sentinel node biopsy for breast cancer?

Tanya S Berrang1, Mary Lesperance, Pauline T Truong, Caroline Walter, Allen H Hayashi, Ivo A Olivotto.   

Abstract

To determine which web-based model best identifies women at low risk of further axillary disease after a positive sentinel lymph node (SLN+) biopsy. 673 women with T1-2cN0M0 SNB+ breast cancer who underwent completion axillary dissection (AxD) were identified. A subgroup not eligible to avoid AxD as part of the Z0011 study was defined (Z0011 exclusion group). Predicted risk of further axillary disease was generated using seven web-based models. "Low risk" was defined as a ≤10% risk of further axillary disease. False negative ("low risk" prediction but AxD+) rates (FNRs), area under the receiver operating characteristic curve (AUC), and Brier score were determined for each model. 6 of 7 models identified "low risk" patients but FNRs ranged from 14 to 30%. The Stanford and Memorial Sloan-Kettering (MSKCC) models had the best FNRs. FNRs were lower with SLN micrometastasis (7-15%) and higher in the Z0011 exclusion group (21-41%). All models under-predicted further nodal disease in low risk patients and over-predicted in higher-risk patients. The Stanford and MSKCC models were able to identify women with SLN micrometastasis with a ≤10% FNR. Models were not able to accurately identify low risk women from a cohort that would have been excluded from Z0011.

Entities:  

Mesh:

Year:  2012        PMID: 22367621     DOI: 10.1007/s10549-012-1991-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  4 in total

1.  Metastatic sentinel node and axillary lymphadenectomy revisited.

Authors:  Laia Bernet; Rafael Cano
Journal:  Gland Surg       Date:  2012-05

2.  Predictive Factors for Non-Sentinel Lymph Node Metastasis in the Case of Positive Sentinel Lymph Node Metastasis in Two or Fewer Nodes in Breast Cancer.

Authors:  Chie Toshikawa; Yu Koyama; Masayuki Nagahashi; Kumiko Tatsuda; Kazuki Moro; Junko Tsuchida; Miki Hasegawa; Toshiyuki Niwano; Naoko Manba; Mayuko Ikarashi; Hitoshi Kameyama; Takashi Kobayashi; Shin-Ichi Kosugi; Toshifumi Wakai
Journal:  J Clin Med Res       Date:  2015-06-09

3.  Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.

Authors:  Hélène Bonsang-Kitzis; Delphine Mouttet-Boizat; Eugénie Guillot; Jean-Guillaume Feron; Virginie Fourchotte; Séverine Alran; Jean-Yves Pierga; Paul Cottu; Florence Lerebours; Denise Stevens; Anne Vincent-Salomon; Brigitte Sigal-Zafrani; François Campana; Roman Rouzier; Fabien Reyal
Journal:  PLoS One       Date:  2017-02-27       Impact factor: 3.240

4.  Intraoperative Nomograms, Based on One-Step Nucleic Acid Amplification, for Prediction of Non-sentinel Node Metastasis and Four or More Axillary Node Metastases in Breast Cancer Patients with Sentinel Node Metastasis.

Authors:  Kenzo Shimazu; Nobuaki Sato; Akiko Ogiya; Yoshiaki Sota; Daisuke Yotsumoto; Takashi Ishikawa; Seigo Nakamura; Takayuki Kinoshita; Hitoshi Tsuda; Yasuyo Ohi; Futoshi Akiyama; Shinzaburo Noguchi
Journal:  Ann Surg Oncol       Date:  2018-07-05       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.